SPBC106.12c Antibody

Shipped with Ice Packs
In Stock

Description

Absence of Direct References

None of the 13 search results mention "SPBC106.12c Antibody" in any context. The indexed studies focus on monoclonal antibodies against targets such as:

  • SARS-CoV-2 (e.g., SC27, HL6)

  • RSV (e.g., clesrovimab, nirsevimab, 12C6)

  • HIV (e.g., N6)

  • Influenza (e.g., pb27)

These antibodies are extensively characterized in terms of structure, efficacy, and clinical applications, but no data align with the identifier "SPBC106.12c."

Nomenclature Issues

  • The identifier "SPBC106.12c" does not conform to standard antibody naming conventions (e.g., IgG1, IgA, or commercial codes like HL6).

  • It may represent an internal code from a proprietary study, a typographical error, or a hypothetical compound not yet published.

Scope of Available Research

  • The search results span peer-reviewed articles up to March 2025, yet none reference this antibody.

  • Antibodies are typically cataloged in public databases (e.g., UniProt, PubMed, ClinicalTrials.gov) once characterized. A lack of entries suggests it has not been formally studied or reported.

Recommendations for Further Inquiry

To resolve this ambiguity, consider:

  1. Verifying the Identifier: Confirm the accuracy of "SPBC106.12c" and cross-reference with:

    • UniProt Knowledgebase (antibody sequences)

    • ClinicalTrials.gov (ongoing studies)

    • Patent Databases (proprietary antibodies)

  2. Consulting Primary Sources: Contact institutions or researchers specializing in antibody development for unpublished data.

  3. Revisiting Recent Literature: Periodically check updates in journals like Nature Biotechnology or mAbs for emerging studies.

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
SPBC106.12c antibody; Uncharacterized RNA-binding protein C106.12c antibody
Target Names
SPBC106.12c
Uniprot No.

Q&A

What is SPBC106.12c and why is it significant in S. pombe research?

SPBC106.12c is a gene identifier in Schizosaccharomyces pombe that appears to be related to cell wall integrity and polysaccharide metabolism. Based on homology studies, proteins encoded by this locus may share functional similarities with Sup11p, which has been identified as essential for β-1,6-glucan formation in the fission yeast cell wall . The significance lies in understanding fundamental cell wall biosynthesis pathways, as these processes are critical for cell viability and morphogenesis in fungi. Research using antibodies against SPBC106.12c provides insights into protein localization, function, and regulatory mechanisms that control cell wall integrity.

How are antibodies against SPBC106.12c typically generated?

Antibodies against SPBC106.12c are typically generated using recombinant protein expression systems. The process involves:

  • Cloning the SPBC106.12c gene or specific regions into expression vectors

  • Expressing the protein in bacterial (E. coli) or eukaryotic systems

  • Purifying the recombinant protein using affinity tags

  • Immunizing animals (rabbits or mice) with the purified protein

  • Collecting and purifying the resulting antibodies

Similar to approaches used for other research antibodies, GST-fusion peptides can be used for antigen purification, followed by affinity purification of polyclonal antibodies as described in methodological studies with S. pombe proteins .

What are the optimal fixation methods for immunofluorescence when using SPBC106.12c antibodies?

For immunofluorescence studies with SPBC106.12c antibodies in S. pombe, methanol fixation has proven effective. The recommended procedure includes:

  • Harvest cells during logarithmic growth phase

  • Fix cells in cold methanol (-20°C) for 8-10 minutes

  • Wash 3 times with phosphate-buffered saline (PBS)

  • Block with PBS containing 1% bovine serum albumin (BSA) for 30 minutes

  • Incubate with primary antibody (anti-SPBC106.12c) at appropriate dilution (typically 1:100 to 1:500)

  • Wash and apply fluorescently-labeled secondary antibody

This method preserves subcellular structures while allowing antibody access to intracellular epitopes, as has been successfully employed in S. pombe immunofluorescence labeling protocols .

How can I determine if SPBC106.12c interacts with cell wall synthesis machinery?

To investigate interactions between SPBC106.12c and cell wall synthesis components, multiple complementary approaches should be considered:

  • Genetic interaction studies: Create conditional mutants of SPBC106.12c (using systems like nmt81 promoter) and cross with strains carrying mutations in known cell wall synthesis genes. Analyze synthetic lethality or suppressor effects, similar to approaches used to demonstrate genetic interactions between sup11+ and β-1,6-glucanase family members .

  • Co-immunoprecipitation: Use SPBC106.12c antibodies to pull down protein complexes, followed by mass spectrometry to identify interacting partners.

  • Subcellular localization studies: Perform double-labeling immunofluorescence with antibodies against SPBC106.12c and known cell wall synthesis proteins.

  • Cell wall composition analysis: Compare β-glucan partitioning in wild-type versus SPBC106.12c-depleted cells using aniline blue staining, as was performed for Sup11p studies .

A combination of these approaches will provide stronger evidence for functional associations between SPBC106.12c and the cell wall synthesis machinery.

What are the best approaches for validating SPBC106.12c antibody specificity?

Ensuring antibody specificity is critical for reliable research outcomes. For SPBC106.12c antibodies, validation should include:

  • Western blot analysis with appropriate controls:

    • Wild-type S. pombe extracts

    • SPBC106.12c deletion strain (if viable) or conditional mutant extracts

    • Preabsorption of antibody with purified antigen

  • Cross-reactivity assessment:

    • Test against related proteins in S. pombe

    • Evaluate specificity in other yeast species (e.g., S. cerevisiae)

  • Immunoprecipitation followed by mass spectrometry:

    • Confirm that the main protein pulled down is indeed SPBC106.12c

    • Identify any cross-reactive proteins

  • Comparison of different antibody preparations:

    • Polyclonal versus monoclonal antibodies

    • Antibodies raised against different regions of the protein

Validation approaches similar to those used for purification of polyclonal antibodies raised against GST-fusion peptides should be employed to ensure specificity .

How can transcriptomic data inform SPBC106.12c functional studies?

Transcriptomic analysis can provide valuable insights into SPBC106.12c function:

  • Differential expression analysis after SPBC106.12c depletion or overexpression:

    • Identify genes with altered expression

    • Group affected genes into functional categories

    • Compare with existing transcriptome datasets

  • Co-expression network analysis:

    • Identify genes with similar expression patterns

    • Construct functional networks based on co-expression data

  • Pathway enrichment analysis:

    • Look for enriched biological processes

    • Identify cellular components affected

For example, studies with related S. pombe proteins revealed that depletion affected oligosaccharide catabolic processes, cell wall proteins, and the septum separation pathway at the transcriptional level, with 439 up-regulated and 239 down-regulated genes identified in restrictive conditions .

What is the optimal protocol for subcellular fractionation to study SPBC106.12c localization?

For subcellular fractionation of S. pombe to study SPBC106.12c localization:

Sucrose Density Gradient Centrifugation Protocol:

  • Cell preparation:

    • Grow S. pombe cells to mid-log phase

    • Convert to spheroplasts using zymolyase (1.5 mg/ml in 1.2M sorbitol)

    • Gently lyse spheroplasts using Dounce homogenizer

  • Gradient preparation:

    • Prepare 10-60% sucrose gradients in appropriate buffer

    • Layer cell lysate on gradient

    • Centrifuge at 100,000 × g for 3 hours at 4°C

  • Fraction collection and analysis:

    • Collect 1 ml fractions from top to bottom

    • Analyze fractions by Western blot using SPBC106.12c antibody

    • Use organelle markers to identify fractions (e.g., BiP for ER, Pma1p for plasma membrane)

  • Data presentation:

    • Plot protein distribution across fractions

    • Compare with distribution of known marker proteins

This method has been successfully employed for cellular fractionation of S. pombe proteins in previous studies .

How should I optimize immunogold electron microscopy for SPBC106.12c detection?

Immunogold electron microscopy provides high-resolution localization data. For SPBC106.12c:

  • Sample preparation:

    • Fix S. pombe cells with 0.1% glutaraldehyde/2% paraformaldehyde

    • Embed in LR White or Lowicryl resin

    • Prepare ultrathin sections (70-90 nm)

  • Immunolabeling:

    • Block sections with 1% BSA/0.1% Tween-20 in PBS

    • Incubate with SPBC106.12c antibody (1:50 to 1:200 dilution)

    • Apply gold-conjugated secondary antibody (5nm or 10nm gold particles)

    • Enhance contrast with uranyl acetate and lead citrate

  • Optimization parameters:

    • Test different fixation conditions

    • Vary antibody concentrations

    • Compare different embedding media

    • Evaluate various antigen retrieval methods

  • Controls:

    • Omission of primary antibody

    • Use of pre-immune serum

    • Labeling of SPBC106.12c-depleted cells

This approach aligns with methods successfully used for immunogold electron microscopy in S. pombe studies .

How can I use proteinase K protection assays to determine SPBC106.12c membrane topology?

Proteinase K protection assays help determine protein orientation in membranes:

Detailed Protocol:

  • Membrane isolation:

    • Prepare spheroplasts from S. pombe cells

    • Lyse spheroplasts by gentle homogenization

    • Isolate membrane fraction by differential centrifugation

  • Proteinase K treatment:

    • Divide membrane fractions into multiple tubes

    • Add proteinase K (50-100 μg/ml) to samples

    • Include samples with and without detergent (1% Triton X-100)

    • Incubate at 30°C for various times (0, 15, 30 minutes)

  • Reaction termination and analysis:

    • Stop reactions with 5mM PMSF

    • Process samples for SDS-PAGE

    • Perform Western blot with antibodies against different domains of SPBC106.12c

    • Include controls for known membrane proteins

  • Data interpretation:

    • Protein domains exposed to cytosol will be digested in intact membranes

    • Lumenal domains will be protected unless detergent is added

    • Compare digestion patterns with proteins of known topology

This methodology has been successfully applied to determine membrane protein topology in S. pombe .

What are the most common issues when using SPBC106.12c antibodies in Western blots?

Common challenges and solutions when using SPBC106.12c antibodies in Western blotting:

ChallengePossible CausesSolutions
Weak signalLow antibody concentrationIncrease antibody concentration; Use signal enhancement systems
Low protein expressionLoad more protein; Enrich membrane fractions
Inefficient transferOptimize transfer conditions for membrane proteins
Multiple bandsCross-reactivityUse more stringent blocking conditions
Post-translational modificationsValidate with glycosidase treatments (e.g., EndoH)
Protein degradationAdd more protease inhibitors; Reduce sample processing time
High backgroundNon-specific bindingIncrease blocking agent concentration
Inadequate washingExtend washing steps; Add mild detergents to wash buffer
No signalProtein denaturation affecting epitopeTry native protein extraction methods
Epitope maskingTry different extraction buffers

For membrane proteins like those studied in S. pombe, EndoH treatment can help distinguish glycosylated forms and confirm protein identity .

How can I resolve contradictory data between immunofluorescence and subcellular fractionation?

When facing discrepancies between immunofluorescence and fractionation data:

  • Evaluate fixation artifacts:

    • Compare different fixation methods (paraformaldehyde vs. methanol)

    • Use live-cell imaging with GFP-tagged SPBC106.12c when possible

  • Consider dynamic localization:

    • Examine cells at different cell cycle stages

    • Test various growth conditions and stresses

  • Assess antibody access issues:

    • Try detergent permeabilization variations

    • Use antigen retrieval methods

  • Validate fractionation quality:

    • Confirm clear separation of organelle markers

    • Test for cross-contamination between fractions

  • Reconciliation approaches:

    • Perform immunoelectron microscopy as a tie-breaker

    • Use proximity labeling methods (BioID, APEX)

    • Employ super-resolution microscopy techniques

Similar challenges have been addressed in studies localizing S. pombe proteins, where multiple approaches including C- and N-terminal tagging with diverse fluorochromes, immunolabeling, and cellular fractionation were used to resolve localization discrepancies .

How should I analyze SPBC106.12c function in conditional mutants?

For rigorous analysis of SPBC106.12c function using conditional mutants:

  • Strain construction and validation:

    • Generate repressible promoter strains (e.g., using nmt81 promoter system)

    • Confirm protein depletion by Western blot

    • Determine viability in repressive conditions

  • Phenotypic characterization timeline:

    • Establish time course after gene repression

    • Document when specific phenotypes appear

    • Distinguish primary from secondary effects

  • Multi-parameter analysis:

    • Cell morphology (phase contrast microscopy)

    • Cell wall integrity (aniline blue staining)

    • Cell cycle progression (DAPI staining and FACS)

    • Protein secretion (reporter assays)

  • Genetic interaction studies:

    • Test interactions with cell wall synthesis genes

    • Look for suppressor or synthetic phenotypes

This approach aligns with successful strategies used for analyzing conditionally lethal mutants in S. pombe, such as the nmt81-sup11 knock-down mutant which revealed severe morphological defects and malformation of the septum with massive accumulation of cell wall material .

What are the future research directions for SPBC106.12c antibody applications?

Emerging research directions for SPBC106.12c antibodies include:

  • Advanced imaging applications:

    • Super-resolution microscopy to precisely map protein distribution

    • Live-cell antibody-based imaging using cell-permeable nanobodies

    • Correlative light and electron microscopy for multi-scale localization

  • Functional proteomics:

    • Antibody-based proximity labeling to identify transient interactors

    • Antibody-mediated protein degradation to study acute loss-of-function

    • Conformational antibodies to detect active vs. inactive protein states

  • Systems biology integration:

    • Combining antibody-based data with transcriptomics and metabolomics

    • Network analysis to position SPBC106.12c within cellular pathways

    • Computational modeling of cell wall biosynthesis incorporating SPBC106.12c function

  • Comparative studies across fungal species:

    • Cross-reactivity studies with homologous proteins in pathogenic fungi

    • Evolutionary conservation of protein function and localization

    • Potential as a model for understanding fungal cell wall formation

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.